Monte Rosa Therapeutics Inc (GLUE)
8.48
-0.15
(-1.74%)
USD |
NASDAQ |
Nov 14, 16:00
8.48
0.00 (0.00%)
After-Hours: 06:48
Monte Rosa Therapeutics Enterprise Value: 258.24M for Nov. 14, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 14, 2024 | 258.24M |
| November 13, 2024 | 267.44M |
| November 12, 2024 | 298.13M |
| November 11, 2024 | 352.14M |
| November 08, 2024 | 306.11M |
| November 07, 2024 | 322.68M |
| November 06, 2024 | 317.77M |
| November 05, 2024 | 312.24M |
| November 04, 2024 | 280.33M |
| November 01, 2024 | 284.01M |
| October 31, 2024 | 259.46M |
| October 30, 2024 | 303.65M |
| October 29, 2024 | 312.86M |
| October 28, 2024 | 319.61M |
| October 25, 2024 | 37.91M |
| October 24, 2024 | 36.68M |
| October 23, 2024 | 36.68M |
| October 22, 2024 | 63.68M |
| October 21, 2024 | 72.28M |
| October 18, 2024 | 76.57M |
| October 17, 2024 | 74.73M |
| October 16, 2024 | 75.35M |
| October 15, 2024 | 52.02M |
| October 14, 2024 | 39.75M |
| October 11, 2024 | 40.36M |
| Date | Value |
|---|---|
| October 10, 2024 | 34.84M |
| October 09, 2024 | 32.38M |
| October 08, 2024 | 44.66M |
| October 07, 2024 | 48.96M |
| October 04, 2024 | 50.18M |
| October 03, 2024 | 51.41M |
| October 02, 2024 | 68.59M |
| October 01, 2024 | 63.07M |
| September 30, 2024 | 63.07M |
| September 27, 2024 | 55.09M |
| September 26, 2024 | 66.75M |
| September 25, 2024 | 75.96M |
| September 24, 2024 | 87.01M |
| September 23, 2024 | 102.96M |
| September 20, 2024 | 135.49M |
| September 19, 2024 | 121.38M |
| September 18, 2024 | 102.96M |
| September 17, 2024 | 101.12M |
| September 16, 2024 | 82.71M |
| September 13, 2024 | 110.94M |
| September 12, 2024 | 103.58M |
| September 11, 2024 | 119.53M |
| September 10, 2024 | 128.13M |
| September 09, 2024 | 101.74M |
| September 06, 2024 | 87.01M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-53.31M
Minimum
Oct 25 2023
1.601B
Maximum
Sep 03 2021
215.77M
Average
111.77M
Median
Aug 22 2023
Enterprise Value Benchmarks
| Novartis AG | 223.14B |
| MEI Pharma Inc | -18.29M |
| Evoke Pharma Inc | 0.1485M |
| Revance Therapeutics Inc | 699.24M |
| Vera Therapeutics Inc | 2.800B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -30.31M |
| Revenue (Quarterly) | 4.695M |
| Total Expenses (Quarterly) | 37.34M |
| EPS Diluted (Quarterly) | -0.43 |
| Profit Margin (Quarterly) | -645.6% |
| Earnings Yield | -26.42% |